




















The role of energy deficits in the development and 
progression of heart failure is well-established and 
cardiac high-energy phosphate levels correlate directly 
with survival in cardiomyopathy patients [1]. In light of 
these clinical observations it has been posited that the 
modulation of mitochondrial function may be a feasible 
strategy to ameliorate heart failure. Aspects of 
mitochondrial function that have been manipulated to 
investigate this include: modulation of energy substrate 
utilization; activation of mitochondrial biogenesis; 
induction of mitochondrial antioxidant defenses and 
suppression of mitochondrial death programs including 
apoptosis and mitochondrial permeability transition.  As 
briefly discussed below, targeting distinct aspects of 
these programs result in variable levels of success and 
suggest that our understanding of the role of the 
mitochondria in the pathophysiology remains in-
complete.   
 
Pharmacologic approaches to modulate mitochondrial 
function have, to date, been limited and have recently 
been reviewed [2,3]. To identify potential novel 
therapeutic targets, genetic approaches have been used 
to directly modulate mitochondrial programming with 
the subsequent assessment of cardiac effects. These 
include the genetic augmentation of PGC-1α, the master 
regulator of mitochondrial biogenesis.  Here, somewhat 
counterintuitively, acute and chronic upregulation of 
PGC-1α results in deleterious cardiac phenotype [4,5]. 
In contrast, the overexpression of mitochondrial 
transcription factor A ameliorates the development of 
ischemia-induced heart failure [6]. The genetic 






















divergent effects. The upregulation of atranscription 
factor promoting fatty acid oxidation, a known major 
cardiac source of energy, is detrimental [7], whereas the 
promotion of glucose uptake enhances cardiac tolerance 
to ischemia [8]. Other approaches include augmentation 
of anti-oxidant enzymes, e.g., by the upregulation of 
cardiac manganese superoxide. These transgenic mice 
are protected against doxorubicin-induced [9] and 
diabetic cardiomyopathy [10]. Augmentation of cardiac 
anti-apoptotic programming by the overexpression of   
Bcl-2 similarly restores mitochondrial function and 
reduces cardiomyopathy in desmin null mice [11].  In 
light of incomplete characterization of proteins involved 
in the mitochondrial permeability transition (MPT) the 
genetic modulation of this program to prevent 
cardiomyopathy has to my knowledge not being 
explored. However, pharmacologic inhibition of MPT 
by cyclosporine A attenuates cardiomyopathy and 
mitochondrial genomic mutagenesis in mice harboring a 
cardiac specific defect in mitochondrial DNA 
proofreading [12]. Taken together, these pharmacologic 
and genetic approaches are beginning to discern distinct 
levels at which mitochondrial reprogramming may have 
beneficial effects in preventing the development and 
progression of heart failure.  
 
An intriguing new finding, by Shultz et al is published 
in AGING regarding the induction of frataxin. 
Mutations in frataxin result in the development of 
Friedreich’s Ataxia, an inherited neurodegenerative 
disease associated with the development of severe 
cardiomyopathy. Frataxin, itself  is involved in 
mitochondrial iron-sulphur cluster biogenesis which 
Mitochondrial Fe-S cluster biogenesis, frataxin and the modulation 
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iron into mitochondrial proteins including aconitase and 
succinate dehydrogenase [13]. Whether frataxin 
functions as an iron-chaperone protein or plays a 
regulatory role in controlling iron and sulphur flux 
within mitochondria is not yet completely characterized. 
Nevertheless, the study by Shultz and colleagues [14] 
shows that increased cardiac frataxin enhances 
tricarboxylic acid cycle function resulting in increased 
cardiac ATP, NADH, NADPH and reduced glutathione 
levels. This array of features is consistent with an 
enhanced bioenergetic capacity and increased 
antioxidant defenses. The authors go on to demonstrate 
that overexpression of frataxin is cardioprotective 
against doxorubicin-induced cardiomyopathy. This 
intriguing study shows that the modulation of the 
mitochondria at the fundamental level of integrating 
cofactors required for protein functional integrity have 
beneficial effects in disease processes that are 
exacerbated by mitochondrial dysfunction. This study 
further highlights the complexity of mitochondrial 
function and adds a new level of regulation operational 
in the pathophysiology of heart failure that may be 
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